September 5, 2018

Immusoft Receives $3.5 Million Grant to Expand upon Its Cell Therapy Platform

SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based cell therapy company, announced today that it has received a Phase II Small Business Innovation Research grant (SBIR) from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH). The grant, in the amount of just over $3.5 million, will enable Immusoft to further advance its modified B cell approach to treating disease. “We appreciate the NIH’s support of our approach,” says Sean A


Leave Comment


Your Name *
Your Email *
Your Website

Comment *